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ABSTRACT
Purpose: Inhaled corticosteroids (ICSs) are often considered an empirical therapy in the 
management of patients with cough. However, ICS responsiveness is difficult to interpret in 
daily clinical practice, as the improvements may include placebo effects or self-remission. We 
aimed to evaluate ICS and placebo treatment effects in adult patients with cough.
Methods: Electronic databases were searched for studies published until June 2018, without 
language restriction. Randomized controlled trials reporting the effects of ICSs compared 
with placebo in adult patients with cough were included. Random effects meta-analyses were 
conducted to estimate the treatment effects. Therapeutic gain was calculated by subtracting 
the percentage change from baseline in the cough score in the ICS treatment group from that 
in the placebo treatment group.
Results: A total of 9 studies were identified and 8 studies measuring cough severity outcomes 
were included for meta-analyses. Therapeutic gain from ICSs ranged from −5.0% to 
+94.6% across the studies included; however, it did not exceed +22%, except for an outlier 
reporting very high therapeutic gains (+45.6% to +94.6%, depending on outcomes). Overall 
ICS treatment effects in cough severity outcomes were small-to-moderate (standardized 
mean difference [SMD], −0.38; 95% confidence interval [CI], −0.54, −0.23), which were 
comparable between subacute and chronic coughs. However, pooled placebo treatment 
effects were very large in subacute cough (SMD, −2.58; 95% CI, −3.03, −2.1), and modest but 
significant in chronic cough (SMD, −0.46; 95% CI, −0.72, −0.21).
Conclusions: Overall therapeutic gain from ICSs is small-to-moderate. However, placebo 
treatment effects of ICS are large in subacute cough, and modest but still significant 
in chronic cough. These findings indicate the need for careful interpretation of ICS 
responsiveness in the management of cough patients in the clinic, and also for rigorous 
patient selection to identify ICS-responders.
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INTRODUCTION
Cough is a physiological reflex to protect the airways, but it can cause a significant morbidity 
when it is dysregulated.1 Cough is also one of the most common symptoms that prompts 
a medical consultation in many countries.2,3 Persistent or chronic cough is prevalent in 
general adult populations and can seriously impair quality of life, as it includes physical, 
psychological, and social consequences.4,5
The identification and treatment of the causes (or treatable traits) of cough is the mainstay 
of current management pathways.6-9 Airway eosinophilic inflammation is one of the major 
treatable traits in subacute or chronic cough, which is commonly labeled as cough variant 
asthma or eosinophilic bronchitis.10,11 However, diagnostic tests for these conditions, such 
as bronchial challenge or induced sputum tests, are technically demanding12,13 and mostly 
restricted to specialist clinics. Thus, inhaled corticosteroids (ICSs) are often considered an 
empirical therapy for cough.14 However, ICS responsiveness is difficult to interpret for cough 
patients in routine clinical practice, as the improvements can include placebo effects or 
period effects (or self-remission).
A Cochrane review published in the Cochrane Library 2013 assessed the effects of ICSs for 
subacute and chronic coughs in randomized controlled trials (RCTs) of adult patients.15 
Here, we re-appraised the literature with up-to-date evidence with a focus on the magnitude 
of placebo treatment effects. To our knowledge, placebo effects have not been reviewed in 
RCTs of ICSs in cough. In this systematic review, we examined therapeutic gains of ICS over 
placebo treatment and also estimated placebo treatment effects in adult patients with cough.
MATERIALS AND METHODS
Literature search
We conducted a systematic search for the following 2 research questions (RQs):
• RQ1. What is the therapeutic gain from ICSs (vs. placebo) in adult patients with cough?
•  RQ2.  What is the magnitude of the placebo effects in ICS trials of adult patients with cough?
We hypothesized that patient factors (cough duration or respiratory comorbidity) and 
intervention factors (inhaler) may make a difference in treatment effects, and thus planned 
subgroup analyses for these parameters. We applied definitions of acute, subacute, 
and chronic coughs based on a cutoff duration of 3 and 8 weeks, as recommended by 
international guidelines.6,16
PubMed, Embase, and Cochrane library databases were systematically searched according 
to the recommendations of the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) statement.17 Our search strategy is summarized in Supplementary 
Table S1 in the online repository. Briefly, it included terms for cough and ICSs using the 
highly sensitive search strategy filter for RCTs suggested by the Cochrane group.18 Articles 
or conference abstracts published in peer-reviewed journals up to June 2018 were searched 
without language restriction. Additional manual searches were performed using Google 
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Scholar, ClinicalTrials.gov, and all cross-referenced articles. The inclusion criteria were as 
follows: 1) Adult patients with cough as the chief complaint, regardless of their underlying 
conditions; 2) ICS intervention; 3) A matched placebo control; 4) Cough outcome reporting 
(before and after treatment); and 5) A randomized double-blind study design. Studies were 
excluded if the population was restricted to children or standard deviations (SDs) for cough 
outcomes could not be obtained. Given possible carry-over effects by ICS treatment, cross-
over trials were also excluded if they did not report the first period results. The study protocol 
was registered as PROSPERO CRD42018100136.
Data extraction
Two independent researchers extracted the following parameters from the articles included: 
first author, journal, publication year, study design, clinical setting, sample size, patient 
selection criteria, patient characteristics, ICS treatment (dose and device), placebo treatment 
(device), treatment duration, and cough outcomes (before and after treatment). If these 
parameters were not described in the reports, but were considered potentially available from 
the original datasets, the corresponding authors were e-mailed to request this information. 
Therapeutic gain was calculated by subtracting the percentage change from baseline in the 
cough score in the ICS treatment group from that in the placebo treatment group.
Quality assessment in individual studies
Risks of bias in the studies included were assessed using the assessment tool from the 
Cochrane Collaboration.19 We intended to assess publication bias using funnel plot 
asymmetry and Egger's regression test.20
Statistical analysis
Random effects meta-analysis was planned as the primary analysis, considering the potential 
methodological and clinical heterogeneity across the studies included. As time is a potential 
determinant for placebo treatment effects, the outcomes measured at similar time points 
(such as 2 or 4 weeks) were selected for primary analyses. Meta-analyses were conducted for 
the outcomes of similar domains (such as cough severity or frequency). Mean differences 
with a 95% confidence interval (CI) were calculated if results were measured using uniform 
scales. If this was not the case, a standardized mean difference (SMD) with a 95% CI was 
estimated for pooled effects. The effect size of the SMD was interpreted in accordance with 
Cohen's rule: small, SMD = 0.2; moderate, SMD = 0.5; and large, SMD = 0.8.21 Heterogeneity 
was first assessed by visual inspection of forest plots, but was also tested using I2 statistics. 
An I2  value greater than 50% was considered significant. All statistical analyses were 
performed using RevMan software, version 5.3 (Cochrane Collaboration, Oxford, UK).
RESULTS
Characteristics of the studies included
The PRISMA flow chart for the literature selection is presented in Fig. 1. A total of 9 RCTs22-30 
met the eligibility criteria. The study by Price et al.27 was included with a data subset for subjects 
with cough. The cross-over study by Chaudhuri et al.31 reported no significant carryover effects, 
but was not included because the first period results were not separately reported. Two other 
studies did not provide SDs for the changes in cough scores,32,33 and thus were not included. A 
search of ClinicalTrials.gov identified 1 unpublished RCT (Identifier: NCT02715167).
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The baseline characteristics of the 9 studies included are summarized in Table 1. All were RCTs 
primarily conducted on adult patients with cough as the chief complaint, regardless of their 
underlying conditions. Based on the cough duration of the study participants (Table 1), 325,26,29 
were classified as studies of acute or subacute cough, and 622-24,27,28,30 as analyses of chronic 
cough. High-dose ICSs were administered in 4 studies,22,26,28,29 and a medium-dose ICSs in 5 
studies.23-25,27,30 The treatment durations ranged from 11 days to 12 weeks. The degree of cough 
was subjectively assessed using a symptom diary or visual analogue scale (VAS) score in all 
studies included. However, an objective cough frequency was measured in only 1 study of acute 
cough (for cough epochs).29 None of the studies included measured cough-specific quality of life.
The participant selection criteria in each study are summarized in Supplementary Table S2. 
A normal chest X-ray result was required for enrollment in 6 studies, whereas the remaining 
3 studies26,27,29 excluded lung parenchymal diseases using medical history only. Three studies 
utilized methacholine or histamine challenge tests to assess airway hyperresponsiveness 
(AHR),22,23,25,30 whereas the others checked bronchodilator responses or medical history for 
screening asthma. Recent corticosteroid exposure history was controlled in 8 studies.22,23,25-30 
Markers for airway eosinophilic inflammation were assessed in 4 studies using the following 
samples or tests: bronchoalveolar lavage,22 induced sputum,23,24 and fractional exhaled nitric 
oxide (FeNO) (Supplementary Table S3).27
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Records identified through database searching
PubMed (n = 1,552), Embase (n = 1,631)
and Cochrane Library (n = 904)
Additional records manually identified
through Google Scholar, ClinicalTrials.gov
and cross-referenced articles (n = 1)
Records excluded after two authors independently
assessed titles and abstracts (n = 3,579)
Records after duplicates removed
(n = 3,801)
Potentially eligible articles
(n = 222)
Studies included in qualitative synthesis
(n = 9)
Studies included in quantitative
synthesis (meta-analysis)
(n = 8)
Full-text articles excluded, with reasons (n = 213)
• Population not relevant (n = 51)
• Intervention not relevant (n = 12)
• No placebo control group (n = 27)
• No cough outcome (n = 78)
• No original data (n = 34)
• Duplicate (n = 6)
• No baseline cough scores (n = 2)
• No standard deviation for cough scores (n = 2)
• Cross-over study not reporting the first period results (n = 1)
Id
en
tifi
ca
tio
n
Sc
re
en
in
g
El
ig
ib
ili
ty
In
cl
ud
ed
Fig. 1. Flow chart of the study selection.
Use of concomitant medications (or no allowance) was described in 6 studies 
(Supplementary Table S4). Five recent RCTs24,26-29 did not allow any medications related to 
the chief complaint; however, 1 study25 allowed the use of mucolytics, β2-agonists, or cough 
suppressants, and measured the frequency of these medications as an outcome.
Risk of bias assessment
Risk of bias assessments is presented in Supplementary Figure. Details of the randomization 
and allocation concealment procedures were not provided in 4 studies.22,25,29,30 The risk of 
reporting bias was unclear in 6 studies (either insufficient information on the number of 
patients assessed for eligibility or insufficient detail in outcome reporting).23-26,28,29 Statistical 
analyses for publication bias, such as funnel plot asymmetry, were not performed as the 
number of studies included in the meta-analysis was less than 10.20
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Table 1. Baseline characteristics of the 9 studies included
Study (yr) Design Cough condition (duration) No. of 
participants
Intervention Control Treatment 
duration (time 
point of outcome 
measurement)
Cough outcomes (score range)
Engel et al. 
(1989)30
Randomized 
double-blind
Chronic bronchitis (cough and 
expectoration for at least 3 
mon a year during at least the 
preceding 2 yr)
18 Medium-dose ICS 
(budesonide 400 mcg 
bid), MDI with spacer
Matching 
placebo
4, 8, 12 wk •  Subjective outcomes: cough 
score (0–3)
Boulet et al. 
(1994)22
Randomized 
double-blind 
(crossover 
design)
Non-asthmatic persistent 
cough (> 4 wk; all subjects had 
cough for longer than 8 wk); 
mean cough duration of 3 yr
14 High-dose ICS 
beclomethasone 
dipropionate 500 mcg 
qid), MDI with spacer
Matching 
placebo
4 wk •  Subjective outcomes: cough 
score (0–10)
Pizzichini et 
al. (1999)23
Randomized 
double-blind
Non-asthmatic chronic cough 
(> 1 yr); mean cough duration 
of 10.8 yr
44 Medium-dose ICS 
(budesonide 400 mcg 
bid), turbuhaler DPI
Matching 
placebo
2 wk •  Subjective outcomes: cough 
severity VAS (0–100)
Ponsioen et 
al. (2005)26
Randomized 
double-blind
Cough of ≥ 2 wk; 90% 
of subjects had acute or 
subacute cough
133 High-dose ICS (fluticasone 
propionate 500 mcg bid), 
MDI with spacer
Matching 
placebo
2 wk •  Subjective outcomes: cough 
diary score (0–6)
Pornsuriyasak 
et al. (2005)25
Randomized 
double-blind
Post-infectious cough (>3 wk); 
95% of subjects had subacute 
cough; mean cough duration 
of 5.3 wk
30 Medium-dose ICS 
(budesonide 400 mcg 
bid), DPI
Matching 
placebo
2, 4 wk •  Subjective outcomes: 
symptom score (1–20: the 
sum of 6 scores including 
cough frequency, cough bout 
frequency, cough associated 
symptom, nigh-time 
cough, frequency of cough 
medications, and number of 
cough medications)
Gillissen et al. 
(2007)29
Randomized 
double-blind
Post-infectious cough (3–14 
days following acute RTI)
72 High-dose ICS (HFA-
budesonide dipropionate 
400 mcg bid), MDI
Matching 
placebo
11 days •  Subjective outcomes: cough 
intensity VAS (0–100)
•  Objective outcomes: cough 
epochs objectively measured 
by Tussometry
Ribeiro et al. 
(2007)28
Randomized 
double-blind
Chronic cough (> 8 wk); mean 
cough duration of 20 wk
64 High-dose ICS (CFC-
beclomethasone 1500 
mcg/day), MDI
Matching 
placebo
2 wk •  Subjective outcomes: cough 
diary score (0–4) for 1) cough 
frequency, 2) cough severity, 
3) duration of coughing, 4) 
sleep interruption and 5) 
Cough severity VAS (0–100)
Rytila et al. 
(2008)24
Randomized 
double-blind
Cough with additional 
respiratory symptoms (> 2 
mo); mean cough duration not 
reported
140 Medium-dose ICS 
(mometasone furoate 400 
mcg), DPI
Matching 
placebo
4, 8 wk •  Subjective outcomes: cough 
diary score (0–3)
Price et al. 
(2018)27
Randomized 
double-blind
Chronic non-specific 
persistent respiratory 
symptoms (> 6 wk); a 
subgroup with cough
235 Medium-dose ICS (QVAR 
80 mcg 2 puff bid), MDI
Matching 
placebo
4 wk •  Subjective outcomes: cough 
severity VAS (0–100)
RTA, respiratory tract infection; ICS, inhaled corticosteroids; MDI, metered dose inhaler; DPI, dry powder inhaler; VAS, visual analogue scale; HFA, 
hydrofluoroalkane; CFC, chlorofluorocarbon.
RQ1. ICS therapeutic gain over a placebo effect in patients with cough
Of the 9 RCTs included in our present review, only 3 studies26-28 reported a significant 
benefit from ICSs over placebo in cough outcomes. Therapeutic gains from ICS treatments 
(calculated by subtracting the percentage change from the baseline cough score in the ICS 
treatment group from that in the placebo treatment group; a positive score indicating a 
benefit from ICSs) ranged from −5.0% to +13.2% in studies of acute29 or subacute cough, 
25,26 and ranged from −19.0% to +94.6% in 6 studies of chronic cough22-24,27,28 (Table 2). The 
extreme range was due to the very high therapeutic gain reported in 1 study28 (+45.6% to 
+94.6%, depending on outcomes). The outlier28 was also identified in a scatter plot analysis 
(Fig. 2); in Spearman's tests, ICS treatment effects (relative change in cough severity score 
from baseline) showed a significant correlation with those of placebo (r = 0.833, P = 0.005). 
The overall therapeutic gain from ICS was less than +22%, except for the single study.28
Random effects meta-analyses were performed for subjective cough severity scores (symptom 
diary or VAS), and were reported in 8 RCTs.22-28,30 One RCT of acute cough patients29 was not 
included here, because it did not report SDs. Overall, the ICS treatment effects were found 
to be small-to-moderate (SMD, −0.38 [95% CI, −0.54, −0.23]; I2 = 46%). However, these 
effects were comparable between subacute (SMD, −0.42 [95% CI, −0.73, −0.10]; I2 = 39%) and 
chronic coughs (SMD, −0.37 [95% CI, −0.55, −0.19]; I2 = 56%) (P = 0.79) (Fig. 3).
Notably, the study showing the best outcomes from ICS treatment28 had a high proportion 
of methacholine-positive patients (50%) and utilized high doses of these drugs (Table 1 and 
Supplementary Table S3). Thus, we performed sensitivity analyses according to the presence 
of AHR and ICS dose, and they were suggested to influence ICS treatment effects; however, 
when the study showing the notably high treatment effects28 is excluded, such differences 
became less remarkable (Supplementary Table S5). ICS treatment effects also did not 
appear to differ by treatment duration (2 vs. 4 weeks), when the outlier study28 was excluded 
(Supplementary Table S5).
Although 4 studies22-24,27 measured airway eosinophilic inflammation, only 1 study27 
was designed to test the associations between this biomarker and the ICS treatment 
responsiveness, and reported significant dose relationships between the baseline FeNO 
levels and ICS treatment effects (Supplementary Table S3). The 2 studies that recruited 
patients with negative methacholine AHR found that none of the subjects tested had airway 
eosinophilia.22,23 One study24 measured the induced sputum eosinophils in a subgroup of 
patients, but found an insignificant association with ICS treatment effects.
RQ2. Placebo treatment effects in patients with cough
Placebo effects (defined by any difference before and after placebo treatment) were 
summarized for each of the cough severity or frequency outcomes (Table 2). Numerically, 
overall placebo treatment effects (%, relative change from the baseline score) ranged from 
−72.9% to −2.2% (a negative score indicating improvement), but with studies of patients 
with acute or subacute cough reporting greater placebo effects (range, −72.9%, −49.6%) than 
those of chronic cough (range, −40.0%, −2.2%). Meanwhile, objective cough frequency was 
only measured in 1 RCT of acute cough (for cough epochs), and the change was −49.6%.29 
Subjective cough frequency score was reported in 1 chronic cough study, which observed a 
relative change of −36.7%.28
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Random effects meta-analyses were conducted for subjective cough severity scores in 8 
RCTs (Fig. 4).22-28,30 Pooled placebo effects yielded an SMD of −0.94 (95% CI, −1.45, −0.44), 
indicating a strong placebo effect overall, but also with a substantial heterogeneity (I2 = 93%). 
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−2 −1 0 1 2
Favours [ICS] Favours [placebo]
Study or subgroup Experimental Control Weight Standard mean difference 
IV, fixed, 95% CI 
Standard mean difference 
IV, fixed, 95% CI Mean SD Total Mean SD Total
1.9.1 Subacute cough
Ponsioen et al. (2005)26 −2.40 1.16 65 −1.90 0.72 68 20.4% −0.52 (−0.86, −0.17)
Pornsuriyasak et al. (2005)25 −7.14 3.73 15 −7.14 2.12 15 4.8% 0.00 (−0.72, 0.72)
Subtotal (95% CI) 80 83 25.1% −0.42 (−0.73, −0.11)
Heterogeneity: χ2 = 1.63, df = 1 (P = 0.20); I2 = 39%
Test for overall effect: Z = 2.64 (P = 0.008)
1.9.2 Chronic cough
Ribeiro et al. (2007)28 −1.19 0.52 44 −0.60 0.50 20 7.6% −1.13 (−1.70, −0.57)
Boulet et al. (1994)22 −1.15 1.56 7 −0.24 0.88 7 2.1% −0.67 (−1.76, 0.42)
Price et al. (2018)27 −19.96 20.89 123 −11.06 21.05 112 36.3% −0.42 (−0.68, −0.16)
Pizzichini et al. (1999)23 −7.70 23.70 23 −3.70 12.10 21 6.9% −0.21 (−0.80, 0.39)
Engel et al. (1989)30 −0.46 0.37 8 −0.43 0.55 10 2.8% −0.06 (−0.99, 0.87)
Rytila et al. (2008)24 −0.58 0.70 61 −0.55 0.58 60 19.2% −0.05 (−0.40, 0.31)
Subtotal (95% CI) 266 230 74.9% −0.37 (−0.55, −0.19)
Heterogeneity: χ2 = 11.34, df = 5 (P = 0.04); I2 = 56%
Test for overall effect: Z = 4.04 (P < 0.0001)
Total (95% CI) 346 313 100.0% −0.38 (−0.54, −0.23)
Heterogeneity: χ2 = 13.04, df = 7 (P = 0.07); I2 = 46%
Test for overall effect: Z = 4.82 (P < 0.00001)
Test for subgroup differences: χ2 = 0.07, df = 1 (P = 0.79); I2 = 0%
Fig. 3. Forest plot of ICS treatment effects stratified by cough duration (subacute vs. chronic cough). Green squares indicate effect size and weight of each study 
for standard mean differences. Black diamonds represent the pooled effect size and 95% CI. 
SD, standard deviation; CI, confidence interval; ICS, inhaled corticosteroids.
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In a visual inspection of the forest plot, 2 studies of subacute cough25,26 showed remarkably 
greater placebo effects compared to those of chronic cough (Fig. 4). Placebo effects were 
calculated as an SMD of −2.58 (95% CI, −3.03, −2.13, I2 = 0%) in 2 studies of subacute 
cough,25,26 indicating a very large effect. However, in 6 studies of chronic cough,22-24,27,28,30 the 
pooled estimate was an SMD of −0.46 (95% CI, −0.72, −0.21; I2 = 69%), indicating a moderate 
effect. Subgroup differences were statistically significant between subacute and chronic 
coughs (P < 0.001) (Fig. 4).
The study by Pizzichini et al.,23 which had the longest cough duration (mean cough duration 
of 10.8 years at baseline; and for at least 1 years in the inclusion criteria), showed the lowest 
placebo effects. Meanwhile, the study by Ribeiro et al.28 showed the greater placebo effects 
among the studies of chronic cough patients, which had a mean cough duration of about 
4 months. In sensitivity analyses by inhaler device, there was a trend toward a greater 
placebo effect in studies using metered dose inhaler than studies using other type of 
inhalers; however, when excluding the outlier study,28 the magnitude of the trend decreased 
(Supplementary Table S6). Treatment duration (2 vs. 4 weeks) did not appear to make a 
difference in placebo effect size; however, longer treatment duration (4 weeks compared to 2 
weeks) showed a trend toward a larger placebo treatment effect when the outlier study28 was 
excluded (Supplementary Table S6).
DISCUSSION
Our present systematic review and meta-analyses summarized the literature on ICS and 
placebo treatment effects in adult patients with cough. The overall ICS therapeutic gains were 
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−4 −2 0 2 4
Favours after placebo Favours before placebo
Study or subgroup Standard mean 
difference
SE Before 
placebo 
Total
After 
placebo 
Total
Weight Standard mean difference 
IV, random, 95% CI 
Standard mean difference 
IV, random, 95% CI 
1.1.1 Subacute cough
Ponsioen et al. (2005)26 −2.648 0.257 68 68 13.0% −2.65 (−3.15, −2.14)
Pornsuriyasak et al. (2005)25 −2.322 0.496 15 12 9.6% −2.32 (−3.29, −1.35)
Subtotal (95% CI) 83 80 22.6% −2.58 (−3.03, −2.13)
Heterogeneity: τ2 = 0.00, χ2 = 0.34, df = 1 (P = 0.56); I2 = 0%
Test for overall effect: Z = 11.30 (P < 0.00001)
1.1.2 Chronic cough
Ribeiro et al. (2007)28 −1.198 0.293 20 20 12.5% −1.20 (−1.77, −0.62)
Price et al. (2018)27 −0.525 0.101 112 112 14.6% −0.53 (−0.72, −0.33)
Rytila et al. (2008)24 −0.499 0.137 73 60 14.3% −0.50 (−0.77, −0.23)
Boulet et al. (1994)22 −0.272 0.385 7 7 11.2% −0.27 (−1.03, 0.48)
Engel et al. (1989)30 −0.2603 0.4496 10 10 10.2% −0.26 (−1.14, 0.62)
Pizzichini et al. (1999)23 −0.143 0.101 25 23 14.6% −0.14 (−0.34, 0.05)
Subtotal (95% CI) 247 232 77.4% −0.46 (−0.72, −0.21)
Heterogeneity: τ2 = 0.06, χ2 = 16.15, df = 5 (P = 0.006); I2 = 69%
Test for overall effect: Z = 3.53 (P = 0.0004)
Total (95% CI) 330 312 100.0% −0.94 (−1.45, −0.44)
Heterogeneity: τ2 = 0.44, χ2 = 101.66, df = 7 (P < 0.00001); I2 = 93%
Test for overall effect: Z = 3.67 (P = 0.0002)
Test for subgroup differences: χ2 = 64.42, df = 1 (P < 0.00001); I2 = 98.4%
Fig. 4. Forest plot of placebo treatment effects stratified by cough duration (subacute cough vs. chronic cough). Red squares indicate effect size and weight of 
each study for standard mean differences. Black diamonds represent the pooled effect size and 95% CIs. 
SE, standard error; CI, confidence interval.
small-to-moderate across the studies we reviewed. However, the improvements in cough 
severity were substantial in the placebo treatment groups; these effects were very large in 
studies of subacute cough patients, but were modest but still significant in studies of chronic 
cough patients. These findings collectively indicate the need for careful interpretation of 
ICS responsiveness in cough patients in the clinic and also for rigorous patient selection to 
identify ICS-responsive patients.
In the current literature, the magnitude of placebo effects has been found to be substantial 
for a variety of chronic medical conditions, including chronic itch,34 pain,35-37 and 
gastrointestinal disorders.38 It is also known that strong placebo effects exist in over-the-
counter medicines for acute cough.39 To our knowledge, placebo effects, however, have not 
been systematically examined for cough that persists for different durations. In our present 
review, we observed placebo effects in the cough severity scores ranging from 50% to 70% 
in studies of acute or subacute cough, but found that they occurred also in studies of chronic 
cough (range, 7.3%, 40%), with an inverse correlation with cough duration trend. In our 
meta-analyses, strong placebo effects were evident in subacute cough (SMD, −2.58 [95% CI, 
−3.03, −2.13]), and modest but significant effects were observed in chronic cough (SMD, 
−0.46 [95% CI, −0.72, −0.21]). As none of the RCTs we reviewed included “no treatment” 
group, the effects we calculated are likely to incorporate period effects (self-remission). The 
inclusion of a “no treatment group” in any future studies would enable a true placebo effect 
from inhaler therapies to be estimated. However, from a clinical perspective, present findings 
suggest that placebo or period effects should be taken into consideration in assessing ICS 
treatment responsiveness in daily practice or when interpreting uncontrolled clinical trials of 
ICS in patients with cough.
We observed only a small-to-moderate overall therapeutic gain from ICSs in studies of 
chronic cough. The gain did not exceed +22% overall in our assessment of cough outcomes 
across the full series of included studies, except for 1 study28 (Table 2). One study reported a 
much greater therapeutic gain in the cough scores of about +45.6% to +94.6% after 2 weeks 
of ICS treatment.28 Our sensitivity analyses indicated that specific patient or intervention 
characteristics (such as the presence of AHR or a higher dose of ICSs) might be related to 
ICS treatment effects; however, when the aforementioned outlier study28 was excluded, the 
sensitivity analysis findings became unremarkable. Hence, it is still unclear whether the 
methacholine AHR or ICS dose can influence ICS treatment responses.
The methacholine AHR parameter did not show any significant associations with ICS 
responsiveness within individual studies24,26,28 (Supplementary Table S3). This lack of a 
relationship may have been attributed to insufficient sample sizes to test the association. 
However, these findings may also be plausible as nonspecific AHR does not well correlate 
with eosinophilic inflammation in the airways40; the latter is one of the main targets of 
corticosteroids. Moreover, eosinophilic bronchitis is common in chronic cough patients 
without AHR,6,11,40 thus limiting the clinical value of nonspecific AHR in predicting ICS 
treatment responses in patients with cough.
Biomarkers for eosinophilic airway inflammation,41 such as FeNO or sputum eosinophilia, 
are suggested to be useful predictors of corticosteroid responsiveness in patients with 
various respiratory conditions.31,40,42-45 However, only 1 placebo-controlled parallel group 
study27 among the reports we here reviewed was designed to test the hypothesis and found 
865https://e-aair.org https://doi.org/10.4168/aair.2019.11.6.856
Inhaled Steroids and Placebo Effects in Cough
significant correlations between baseline FeNO levels and improvement in the cough VAS 
score (defined as a decrease of at least 20 mm) in the ICS treatment group. Further studies 
are warranted to confirm the utility of practical biomarkers, such as FeNO, to identify ICS 
responders in chronic cough.
Our study had several limitations of note. First, cough outcomes employed by the studies 
included (i.e., VAS and cough scores) were heterogeneous and poorly validated. The cough 
VAS score was utilized in a few studies23,27-29 and is a common useful tool to assess cough 
severity in the practice. However, there is a lack of published data reporting its validity and 
the minimal important difference.46 Other studies included utilized cough diary scores in 
different scales. 22,24-26,30 Hence, our estimation of the treatment effects relied on an SMD 
scale, which is a relative measure. Utilization of validated objective cough frequency or 
cough-specific quality-of-life scores will facilitate more precise interpretation of ICS and 
placebo treatment effects in patients with cough. Secondly, none of the studies we reviewed 
had a “no treatment arm,” and the estimated placebo effects could not be differentiated from 
period effects. Thirdly, we did not perform formal statistical tests for assessing publication 
bias, as the number of studies included in the meta-analysis was small.20 In our opinion, the 
placebo treatment effects are less prone to publication bias than the ICS treatment effects, as 
the former was not primary outcome in the original RCTs. We sought to reduce publication 
bias by searching Clintrials.gov database for unpublished studies and by having no restriction 
by publication language or type (such conference abstract) in the literature selection process. 
Finally, our current findings may not be extrapolated to clinical trials of pharmacological 
treatments other than ICSs.
In conclusion, overall therapeutic gain from ICS may be modest in cough patients. However, 
the placebo effects of ICSs are large in subacute cough, and modest but still significant 
in chronic cough. Specific patient or intervention factors (such as asthmatic traits or 
treatment doses) may be associated with better treatment outcomes, but there is limited 
evidence that confirms these relationships. Our present findings of placebo treatment 
effects indicate that ICS treatment responsiveness should be cautiously interpreted in daily 
clinical practice or in uncontrolled clinical trials of cough patients. Given a considerable 
proportion of ICS-responsive cough (cough variant asthma and eosinophilic bronchitis) in 
the clinics, an empirical trial of ICS may be justified, but a stopping rule needs to be part of 
the management. In addition, further studies are warranted to identify and validate practical 
biomarkers for prediction of ICS responsiveness in patients with cough.
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